Supernus Pharma (SUPN) Misses Q1 EPS by 2c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.29, $0.02 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $153.76 million versus the consensus estimate of $137.74 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Cloudastructure restructures preferred stock, issues $1.3M promissory note